Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Global Forecast 2024-2030

Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Global Forecast 2024-2030

The Atherosclerosis Drugs Market size was estimated at USD 22.59 billion in 2023 and expected to reach USD 23.82 billion in 2024, at a CAGR 5.66% to reach USD 33.23 billion by 2030.

Atherosclerosis drugs refer to a variety of medications designed to slow or reverse the buildup of plaque in the arteries, a condition known as atherosclerosis. This buildup can lead to heart disease, stroke, and other cardiovascular issues. The major factors contributing to the expansion of their use include the rising prevalence of cardiovascular diseases globally, increased awareness and diagnosis rates, advancements in drug development, and a growing aging population at higher risk of developing atherosclerosis. However, these drugs are not without their challenges, such as potential side effects, varying efficacy among individuals, and the high cost of treatment, particularly with newer, patent-protected medications. Addressing these issues requires ongoing research to develop more effective and safer medications, implement strategies to reduce healthcare costs, and improve patient education on lifestyle changes that can complement drug therapy. Biotechnology advancements and personalized medicine approach that tailor treatment to the individual's genetic makeup is expected to diversify the opportunities for the improved development of atherosclerosis drugs.

Regional Insights

The Americas showcases significant atherosclerosis drug development, backed by robust R&D infrastructure, significant healthcare expenditure, and a strong presence of leading pharmaceutical companies. This region benefits from advanced healthcare frameworks and favorable government policies promoting drug innovation and quick adoption. Conversely, the APAC region, led by countries such as China, Japan, and India, is experiencing rapid growth in the atherosclerosis drugs market. This surge is powered by increasing healthcare awareness, rising cardiovascular disease prevalence, and improving healthcare infrastructures. However, APAC's market is more fragmented with a mix of local and international players, and there is a rising focus on generic drug production due to cost sensitivity in the region. On the other hand, EMEA presents a mature market scenario with stringent regulatory standards and a strong emphasis on drug efficacy and safety. The European Union's unified regulatory framework under the European Medicines Agency (EMA) facilitates a streamlined process for drug approval across member states yet poses challenging market entry barriers for new players. The Middle East and Africa segment of EMEA, while smaller in market size, is gradually expanding, owing to increasing investment in healthcare infrastructure and a growing focus on chronic disease management.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Atherosclerosis Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing prevalence of CVDs and atherosclerosis diseases
• Initiatives promoting diagnosis and early treatment of heart diseases

Market Restraints

• Risk of recalls of atherosclerosis drugs

Market Opportunities

• Ongoing research projects for introducing advanced atherosclerosis drugs
• Rising government approvals for atherosclerosis drugs

Market Challenges

• Complications of new atherosclerosis drug development

Market Segmentation Analysis

• Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
• Distribution Channel: Improved availability of atherosclerosis drugs through online channels

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Atherosclerosis Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Atherosclerosis Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease

The National Heart, Lung, and Blood Institute (NHLBI) bestowed a grant of USD 1.14 million upon The Texas Heart Institute® (THI) for an initiative over the span of two years. This funding aims to support the development of an innovative, premiere drug designed to enhance the treatment landscape for cardiovascular disease (CVD), with a particular focus on mitigating complications associated with atherosclerosis. This endeavor marks a significant stride towards advancing therapeutic options and improving outcomes for individuals grappling with the ramifications of this prevalent condition.

US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C

The US Food and Drug Administration (FDA) approved an important label update for Novartis's Leqvio (inclisiran), now allowing its earlier application in managing elevated LDL-cholesterol (LDL-C) levels among patients at heightened heart disease risk, alongside diet and statin therapy. The recent modification broadens its indication to include patients with primary hyperlipidemia, fostering its application beyond the confines of atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).

Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA

The U.S. Food and Drug Administration (FDA) granted approval to Lodoco (colchicine) for reducing the likelihood of myocardial infarction, stroke, coronary revascularization, and cardiovascular mortality among adults. This milestone gives Agepha Pharma the accolade of creating the inaugural medication specifically designed to mitigate the inflammation associated with atherosclerotic cardiovascular disease. Thus, Lodoco emerges as a therapeutic advance and a beacon of hope for enhancing the quality of life for individuals grappling with atherosclerotic cardiovascular diseases.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Atherosclerosis Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Atherosclerosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agepha Pharma US, Amgen Inc., Anthos Therapeutics, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cardurion Pharmaceuticals, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., NewAmsterdam Pharma, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Atherosclerosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Class
• Anti-Hypertensive Drugs
• Antiplatelet Agents
• Cholesterol-lowering Drugs
• Route of Administration
• Injectable
• Oral
• Disease Stage
• Atheroma Formation
• Atherosclerotic Plaques Formation
• Fatty Streaks Formation
• Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year